VetSheet

フルルビプロフェン

Flurbiprofen

2-(2-fluoro-4-biphenylyl)propionic acid

別名: Ocufen · Flurbiprofeno · Flurbiprofenum

VetSheet 獣医チームが監修更新日 2026年4月5日エビデンスに基づく獣医学リファレンス

1 drop in the affected eye(s)Topical· Every 30 minutes for 4 doses prior to surgery· Pre-operative

用量は獣医専門家向けの臨床参考資料です。必ず最新の医薬品情報および個別症例に基づいて確認してください。

動物種別用量

🌎 NA — North America🌍 EU — Europe

適応用量経路頻度期間地域
Prevention of intraocular surgical miosis1 drop in the affected eye(s)TopicalEvery 30 minutes for 4 doses prior to surgeryPre-operative🌍 EU
Ocular inflammation (uveitis)1 drop in the affected eye(s)Topicalq6h to q12hAs directed by veterinarian🌍 EU
  • Prevention of intraocular surgical miosis: Standard pre-surgical protocol
  • Ocular inflammation (uveitis): Monitor for corneal ulceration

適応用量経路頻度期間地域
Prevention of intraocular surgical miosis1 drop in the affected eye(s)TopicalEvery 30 minutes for 4 doses prior to surgeryPre-operative🌍 EU
Ocular inflammation (uveitis)1 drop in the affected eye(s)Topicalq6h to q12hAs directed by veterinarian🌍 EU
  • Prevention of intraocular surgical miosis: Standard pre-surgical protocol
  • Ocular inflammation (uveitis): Monitor for corneal ulceration

用量は獣医専門家向けの臨床参考資料です。必ず最新の医薬品情報および個別症例に基づいて確認してください。

診察中ですか?VetSheet の AI が薬剤・用量・投与期間を構造化された診察記録に直接記入します。VetSheet の仕組みを見る

概要

フルルビプロフェンは局所眼用非ステロイド性抗炎症薬(NSAID)です。主に眼内手術(白内障手術など)中の術中縮瞳の予防や、眼の炎症の管理に使用されます。

​臨床のポイント:​ 前ぶどう膜炎の制御や手術誘発性の縮瞳の予防には非常に効果的ですが、フルルビプロフェンのような局所NSAIDは角膜上皮の治癒を遅らせる可能性があるため、既存の角膜潰瘍がある患者には細心の注意を払って使用する必要があります。

作用機序

Inhibits ​cyclooxygenase (COX)​ enzymes, thereby blocking the synthesis of prostaglandins from arachidonic acid. → Reduces ocular inflammation and provides analgesic action. → Prevents prostaglandin-mediated miosis (constriction of the iris sphincter) during intraocular surgery, acting independently of cholinergic mechanisms.

安全性・警告

禁忌

  • Hypersensitivity to flurbiprofen or other NSAIDs
  • Active corneal ulceration (relative contraindication)
  • Bleeding disorders
  • Hypersensitivity to NSAIDs
  • Active intraocular bleeding
  • Corneal ulceration (use with extreme caution)
  • Epithelial herpes simplex keratitis

有害事象

  • Transient ocular stinging or burning upon application
  • Delayed corneal healing
  • Increased risk of ocular bleeding during surgery
  • Corneal melting (rare but severe)
  • Transient stinging or burning upon instillation
  • Ocular irritation
  • Increased bleeding tendency of ocular tissues (rare)

注意事項

​Warning:​ May delay corneal epithelial healing. Use with extreme caution in patients with pre-existing corneal ulcers or epithelial defects. Monitor closely for signs of corneal melting or worsening ulceration.

​Clinical Pearl:​ Patients with a known bleeding tendency or those receiving systemic medications that prolong bleeding time should be monitored closely, as topical NSAIDs may increase bleeding of ocular tissues during surgery.

医薬品相互作用

Topical CorticosteroidsModerate

Concurrent use may increase the risk of delayed corneal healing and severe complications such as corneal melting.

Topical Prostaglandin Analogues (e.g., Latanoprost)Minor

NSAIDs may blunt the intraocular pressure-lowering efficacy of topical prostaglandins.

Topical prostaglandins (e.g., Latanoprost)Minor

NSAIDs may decrease the intraocular pressure-lowering efficacy of topical prostaglandin analogues.

監視

  • Resolution of ocular inflammation (flare and cells in the anterior chamber)
  • Intraocular pressure (IOP)
  • Maintenance of pupillary dilation during surgery
  • Corneal integrity (via fluorescein staining) if used long-term

薬物動態

半減期

Unknown for topical administrationUnknown for topical administration

吸収

Absorbed systemically through the nasolacrimal duct and conjunctival vessels, but systemic levels remain very low.

分布

Penetrates the cornea well to reach therapeutic concentrations in the aqueous humor.

代謝

Hepatic (for the small fraction that is systemically absorbed).

消失

Renal (for systemically absorbed drug).

過剰投与

Topical overdose is unlikely to cause systemic toxicity due to the small volume administered. Ocular overdosage may lead to increased local irritation, hyperemia, and delayed corneal healing. If significant overexposure occurs, flush the eye with sterile saline.

製品

製剤

  • Ophthalmic: 0.03% solution in single-use vials

ヒト用医薬品

  • Ocufen 0.03% eye drops (single-use vials)
  • Ocufen 0.03% ophthalmic solution (single-use vials)

規制ステータス

United States✓ 承認済み処方箋医薬品FDA
human

Used off-label in veterinary ophthalmology.

European Union✓ 承認済み処方箋医薬品EMA

POM (Prescription Only Medicine)

United Kingdom✓ 承認済み処方箋医薬品VMD

POM (Prescription Only Medicine)

規制データなし: 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU

保管・安定性

Store at room temperature (15-25°C). Protect from light. Single-use vials do not contain preservatives and should be discarded immediately after use.

飼主向け情報

獣医師の処方通りに点眼薬を投与してください。汚染を防ぐため、点眼容器の先端が目や眼瞼、その他の表面に触れないようにしてください。複数の点眼薬を使用する場合は、少なくとも5分間隔を空けてください。ペットの目がさらに赤くなったり、痛がったり、濁ったり、目を細めたり、目をこすり始めたりした場合は、すぐに獣医師に連絡してください。

VetSheet医薬品リファレンスは獣医専門家の臨床意思決定支援を目的としており、専門的判断または製造業者の最新医薬品情報の代替にはなりません。